---
title: "Shanghai Pharma: Mao Jianyi resigns from the position of Vice President"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258857910.md"
description: "According to the Zhitong Finance APP, Shanghai Pharma announced that on September 25, 2025, the company's board of directors received a written resignation letter from Mr. Mao Jianyi. Due to a job transfer, Mr. Mao Jianyi resigned from his position as vice president of the company. The resignation letter takes effect from the date it is delivered to the company's board of directors. After his resignation, Mr. Mao Jianyi will no longer serve as vice president of the company but will continue to hold the position of chairman of the subsidiary companies Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. and Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd"
datetime: "2025-09-25T10:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258857910.md)
  - [en](https://longbridge.com/en/news/258857910.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258857910.md)
---

# Shanghai Pharma: Mao Jianyi resigns from the position of Vice President

According to the Zhitong Finance APP, Shanghai Pharma (02607) announced that on September 25, 2025, the company's board of directors received a written resignation letter from Mr. Mao Jianyi. Due to a job transfer, Mr. Mao Jianyi resigned from his position as Vice President of the company. The resignation letter takes effect from the date it is delivered to the company's board of directors. After his resignation, Mr. Mao Jianyi will no longer serve as Vice President of the company but will continue to hold the position of Chairman of the subsidiary companies Shanghai Shyangyi Pharmaceutical Co., Ltd. and Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd

### Related Stocks

- [601607.CN](https://longbridge.com/en/quote/601607.CN.md)
- [02607.HK](https://longbridge.com/en/quote/02607.HK.md)

## Related News & Research

- [<![CDATA[Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman]]>](https://longbridge.com/en/news/284904216.md)
- [CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate](https://longbridge.com/en/news/284559073.md)
- [Joe Scarborough Mocks Pete Hegseth’s 'Petulant' Attitude At Hearing With Savage New Term](https://longbridge.com/en/news/284826458.md)
- [Pharmaron Beijing Issues Unaudited First-Quarter 2026 Report Under Hong Kong Rules](https://longbridge.com/en/news/284364965.md)
- [Modern Chinese Medicine Group to Modernise Articles of Association with Digital and Governance Upgrades](https://longbridge.com/en/news/284414771.md)